Kairos Pharma, Ltd. (KAPA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 10, 2025, for Kairos Pharma, Ltd., a Delaware corporation trading on NYSE American under the symbol KAPA. The filing details the entry into a material definitive agreement and the results of the Company's Annual Meeting of Stockholders.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed relates to a new contractual obligation:
- Services Agreement Fee: $170,000 total fee payable over one year in monthly increments to Barretto Pacific Corporation (BPC) for investor relations and public information dissemination services.
Material Changes and Corporate Actions
The following material events were reported:
- Material Definitive Agreement: Entered into a one-year Services Agreement with BPC for investor relations services.
- Annual Meeting Results:
- Director Elections: All four nominees (John S. Yu, M.D.; Hyun W. Bae, M.D.; Hansoo Michael Keyoung, M.D., Ph.D.; Rahul Sighvi, Sci.D., MBA) were elected with overwhelming support (approx. 10.37 million votes "For" each) and zero votes "Against".
- Auditor Ratification: Stockholders ratified Weinberg & Company, P.A. as the independent auditor (approx. 11.13 million "For" vs. 31,741 "Against").
- Executive Compensation: Advisory approval granted for executive compensation (approx. 10.02 million "For" vs. 16,834 "Against").
- Compensation Vote Frequency: Stockholders approved annual advisory votes on executive compensation (approx. 10.04 million "For" 1-year option).
- Stock Issuance Approval: Stockholders approved the issuance of in excess of 20% of common stock at a price below the "Minimum Price" in compliance with NYSE American rules (approx. 10.76 million "For" vs. 623,989 "Against").
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or specific risk factors beyond the standard disclosure that the summary of the Services Agreement is qualified by the full text of the agreement. The approval of stock issuance below the minimum price indicates a potential future dilution event, though specific terms of such issuance are not detailed in this report.
Investor Verification Checklist
- Verify the full text of the Services Agreement with Barretto Pacific Corporation (Exhibit 99.1) for specific deliverables and termination clauses.
- Monitor future filings for details regarding the issuance of common stock approved under the "Minimum Price" exception, as this may impact share count and dilution.
- Review the Company's next periodic report (10-K or 10-Q) for updated liquidity and cash position, as this 8-K does not provide current financial status.
- Confirm the composition of the Board of Directors following the election of the four nominees.